Introduction {#Sec1}
============

Patient-reported outcomes (PROs) used in clinical practice and clinical research are health outcomes reported directly by the patient, without interpretation or confirmation from an intermediary, such as a physician, nurse, or study coordinator \[[@CR1]\]. In 2004, the National Institutes of Health roadmap for clinical research identified the development of PROs as a key priority, and multiple PRO tools have been created and validated \[[@CR2]--[@CR14]\]. Guidelines have been published recommending best practices for PRO use \[[@CR15]\], and there have been calls to comprehensively integrate PROs into cardiovascular clinical trials \[[@CR16]\]. PROs have been used to compare patient satisfaction with warfarin versus the direct oral anticoagulants (DOACs), and have found higher satisfaction with DOACs in patients with pulmonary embolism (PE) \[[@CR17]\], deep venous thrombosis (DVT) \[[@CR18]\], and atrial fibrillation (AF) \[[@CR19]--[@CR21]\]. However, these studies did not examine whether increased satisfaction predicts better medication adherence. Nonadherence precludes treatment efficacy and leads to worse outcomes \[[@CR22]\], and in clinical trials, study drug discontinuation can undermine the scientific rigor of the study. The objective of this substudy from The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) \[[@CR23]\] was to determine if PROs assessing study drug satisfaction are associated with study drug discontinuation. We hypothesized that patients who were more satisfied with the study drug would be less likely to discontinue the study drug.

Methods {#Sec2}
=======

The design of ROCKET AF (NCT00403767) has been previously described \[[@CR23]\]. In brief, ROCKET AF was a phase III, randomized, double-blind, placebo-controlled, multicenter trial of rivaroxaban compared with dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with nonvalvular AF. A total of 14,264 patients were randomized at 1178 centers in 45 countries. The protocol was approved by ethics committees at participating sites, and all patients provided written informed consent. Patients were included if they had moderate-to-high risk for stroke. Patients were randomized to rivaroxaban 20 mg once daily, or 15 mg once daily in patients with a creatinine clearance of 30--49 mL/min, or dose-adjusted warfarin with a target international normalized ratio of 2.0--3.0. It was intended that patients would continue the therapy throughout the duration of the trial, unless discontinuation was clinically indicated, or after meeting a primary endpoint in which case discontinuation was mandated.

A subset of patients in ROCKET AF was given two treatment satisfaction questionnaires: The Anti-Clot Treatment Scale (ACTS) and the Treatment Satisfaction Questionnaire for Medication version II (TSQM II). Both scales are validated \[[@CR24]--[@CR27]\] and have been used extensively in previous trials of anticoagulants \[[@CR17]--[@CR21], [@CR28]\]. The subset of patients given the questionnaires was selected at random from pre-selected sites in the USA, Germany, and The Netherlands. Sample size calculation was not performed, as these analyses examining PROs and study-drug discontinuation were not preplanned at the start of ROCKET AF.

The ACTS is a 15-item patient-reported instrument of satisfaction with anticoagulant treatment and is summarized as two scales that represent both negative and positive aspects of anticoagulation treatment: ACTS Burdens (12 items), and ACTS Benefits (3 items). The ACTS is an adaptation of the previously validated Duke Anticoagulation Satisfaction Score \[[@CR29]\]. For each item, patient experience with anticoagulation treatment is rated on a five-point Likert scale from "Not at all" to "Extremely." The 12 items of ACTS Burdens are reverse coded (scored 5--1), whereas the three items of ACTS Benefits are coded normally (scored 1--5), so that higher scores indicate greater patient satisfaction. Item scores are summed across domains to give an ACTS Burdens score ranging from 12 to 60 and an ACTS Benefits score ranging from 3 to 15. A patient must have data for all items of a scale for the scale to be calculated. The ACTS was measured at 4, 8, 12, and 24 weeks after randomization.

The TSQM II consists of ten items representing four scales: Effectiveness (2 items), Side Effects (3 items), Convenience (3 items), and Global Satisfaction (2 items). Experiences of treatment satisfaction are rated on five-point and seven-point Likert scales from "Extremely dissatisfied" to "Extremely satisfied," with scale scores being converted to a score between 0 and 100, where higher scores indicate greater satisfaction with treatment. A patient must have data for all items of a scale in order for the scale to be calculated, except for the Side Effects and Convenience scales, for which up to one item each could be missing. The TSQM II was measured at 4 and 24 weeks after randomization.

The current analysis includes data from both questionnaires at 4 and 24 weeks, the time points at which both surveys were carried out. Our primary analysis examines survey responses at 4 weeks, a time point that is far enough into the course of therapy to gauge satisfaction, but potentially early enough to intervene before discontinuation occurs. In addition, we examined longer-term satisfaction using data at 24 weeks. Patients who were randomized and received at least one dose of study drug were included in the analysis if they had complete data for both ACTS and TSQM II at 4 weeks and were still on the assigned study drug at the 4-week visit.

Details about study drug administration were collected rigorously including timing, duration, and reason for interruptions or discontinuation of study drug. Study drug discontinuation was defined as a permanent discontinuation of randomized study drug (i.e., stopping study drug and not starting it again later). Temporary interruptions of study drug, defined as stopping study drug and starting it again later (for example for a surgical procedure), were not included as discontinuation outcomes. These discontinuation definitions were used across all ROCKET AF analyses that considered discontinuation in any way \[[@CR30]\]. Discontinuations were classified as patient-driven discontinuation or non-patient-driven discontinuation. Patient-driven discontinuation was defined as stopping study drug due to any of the following reasons: withdrawal of consent, noncompliance, or loss to follow-up. Non-patient-driven discontinuation was defined as discontinuation for any other reason (e.g., adverse event, clinical efficacy endpoint reached, investigator decision, protocol violation).

Baseline characteristics and reasons for discontinuation are summarized using number (percent) for categorical variables and median (25th, 75th percentiles) for continuous variables. Scores for individual scales are summarized using both median (25th, 75th percentiles) and mean (standard deviation). These scale summaries were carried out for both 4-week and 24-week data.

Patients were categorized as satisfied or not satisfied in two ways, using 4-week data. For our primary analysis, for each scale, we found the minimum score reflecting satisfaction (e.g., an answer of Satisfied, Very Satisfied, or Extremely Satisfied for all score components; details in the Supplemental Appendix). A patient was then considered satisfied at 4 weeks if their score was equal to or greater than this minimum score (see Supplemental Appendix: Definition of "satisfied vs. "not satisfied" for each scale; minimum score for satisfaction for each subscale was: ACTS Benefits \> 12, ACTS Burdens \> 42, TSQM Effectiveness \> 66.67, Side Effects \> 100, TSQM Convenience \> 66.7, TSQM Global Satisfaction \> 66.7). For our sensitivity analysis, to address any possible subjectivity in our definition for the primary analysis, we used the median of each score distribution as the minimum score cut-off to define satisfaction.

Rates of patient-driven discontinuation after the 4-week survey are summarized for satisfaction groups using events per 100 patient-years and total events. To formally test this relationship, we used Fine and Gray models, which are semi-parametric proportional hazards models that account for competing risks, in this case, non-patient-driven discontinuation. Start time for the models was the time of the 4-week questionnaire. Models were adjusted for the following variables found to be predictive of patient-driven discontinuation in the full ROCKET AF cohort (details of model development are in the Supplemental Appendix): age, sex, race, geographic region, prior stroke or transient ischemic attack, history of depression, prior vitamin K antagonist (VKA) use, and post-randomization occurrence of bleeding or a temporary interruption of study drug for a procedure. Risk relationships are presented as hazard ratios with 95% confidence intervals.

All analyses were conducted using SAS version 9.4 or higher (SAS Institute Inc., Cary, NC).

Results {#Sec3}
=======

Of 14,264 patients in ROCKET AF, 1577 participated in the Patient Satisfaction substudy and 1181 remained on study drug at 4 weeks and completed both the ACTS and TSQM II questionnaires 4 weeks after starting the study drug. Of these patients, 572 (48.4%) had been randomized to rivaroxaban, 609 (52.6%) to warfarin. Baseline demographic characteristics were similar in the two groups (Table [1](#Tab1){ref-type="table"}). A total of 855 patients completed both the ACTS and TSQM II at 24 weeks (72% of those who completed both questionnaires at 4 weeks), including 398 (46.5% of those who completed both questionnaires at 24 weeks) randomized to rivaroxaban, and 457 (53.4% of those who completed both questionnaires at 24 weeks) randomized to warfarin.Table 1Baseline characteristics for patients participating in the patient satisfaction surveysVariableAll patients (*N* = 1181)Rivaroxaban (*N* = 572)Warfarin (*N* = 609)Randomized to rivaroxaban572 (48%)Age (years)75 (67, 79)75 (67, 79)75 (67, 79)Female sex398 (34%)189 (33%)209 (34%)Geographic region North America776 (66%)373 (65%)403 (66%) Western Europe405 (34%)199 (35%)206 (34%)Type of AF Persistent881 (75%)423 (74%)458 (75%) Paroxysmal286 (24%)139 (24%)147 (24%) New onset14 (1%)10 (2%)4 (1%)CHADS~2~ score, mean (SD)3.2 (1.0)3.2 (1.0)3.2 (1.0)CHADS~2~ score 2316 (27%)146 (26%)170 (28%) 3471 (40%)228 (40%)243 (40%) 4270 (23%)137 (24%)133 (22%) 596 (8%)47 (8%)49 (8%) 628 (2%)14 (2%)14 (2%)Presenting characteristics BMI (kg/m^2^)29.8 (26.3, 33.8)29.9 (26.6, 34.3)29.8 (26.0, 33.5) SBP (mmHg)130 (120, 140)130 (120, 140)130 (120, 142) DBP (mmHg)78 (70, 85)78 (70, 85)78 (70, 85) Heart rate (bpm)72 (63, 82)72 (63, 81)72 (63, 82) Creatinine clearance^a^ (mL/min)70 (54, 93)72 (55, 94)69 (53, 93)Baseline comorbidities Prior stroke/TIA/embolism464 (39%)225 (39%)239 (39%) Congestive HF585 (50%)286 (50%)299 (49%) Prior MI248 (21%)122 (21%)126 (21%) PAD84 (7%)34 (6%)50 (8%) Hypertension1092 (92%)531 (93%)561 (92%) Diabetes540 (46%)263 (46%)277 (45%) COPD181 (15%)94 (16%)87 (14%)Medications Prior VKA use1020 (86%)489 (85%)531 (87%) Prior chronic aspirin use324 (27%)158 (28%)166 (27%) ACE inhibitor/ARB at baseline894 (76%)444 (78%)450 (74%) Beta blocker at baseline866 (73%)410 (72%)456 (75%) Digitalis at baseline443 (38%)207 (36%)236 (39%) Diuretic at baseline749 (63%)366 (64%)383 (63%)Continuous variables are shown as median (25th, 75th percentiles) except where noted, and categorical variables as no. (%)*ACE* angiotensin converting enzyme, *AF* atrial fibrillation, *ARB* angiotensin receptor blocker, *BMI* body mass index, *bpm* beats per minute, *CHADS*~*2*~ congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, *COPD* chronic obstructive pulmonary disease, *DBP* diastolic blood pressure, *HF* heart failure, *MI* myocardial infarction, *PAD* peripheral artery disease, *SBP* systolic blood pressure, *SD* standard deviation, *TIA* transient ischemic attack, *VKA* vitamin K antagonist^a^Calculated using the Cockcroft--Gault equation

Patient satisfaction measures at 4 weeks after randomization, overall and by randomized treatment, are presented in Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. As expected, because of the double-blind design, no differences were observed between the randomized treatment arms in any scales.Table 2ACTS and TSQM scores at 4 weeks after randomization, overall and by randomized treatmentQuestionnaire/ScaleAll patients (*N* = 1181)Rivaroxaban (*N* = 572)Warfarin (*N* = 609)*P* valueACTS ACTS Burdens57 (54, 59)57 (54, 59)57 (53, 59)0.2055.6 (5.0)55.9 (4.7)55.4 (5.2) ACTS Benefits12 (10, 14)12 (10, 14)12 (9, 14)0.5411.3 (3.1)11.4 (3.0)11.3 (3.2)TSQM II Effectiveness67 (67, 83)67 (67, 83)67 (67, 83)0.6871.9 (19.1)72.1 (19.1)71.6 (19.1) Side Effects100 (92, 100)100 (92, 100)100 (92, 100)0.4893.2 (14.9)92.8 (15.9)93.6 (13.9) Convenience78 (67, 89)78 (67, 89)78 (67, 83)0.2677.2 (14.8)77.7 (15.3)76.8 (14.4) Global Satisfaction75 (67, 83)75 (67, 83)75 (67, 83)0.2475.4 (16.1)75.9 (16.4)74.9 (15.9)For each scale, the top entry is median (25th, 75th percentiles) score and the bottom entry is mean (SD)*ACTS* Anti-Clot Treatment Scale, *TSQM II* Treatment Satisfaction Questionnaire for Medication version IIFig. 1Scales of patient satisfaction for the entire analysis cohort and by randomized treatment at 4 weeks after randomization

In the longer term, satisfaction scores at 24 weeks were similar to those at 4 weeks (Supplemental Table 1 and Supplemental Figure 1), indicating that levels of satisfaction remained consistent over time.

Over a median follow-up of 1.6 years, 448 early permanent study drug discontinuations occurred; 116 (26%) of those were patient-driven (Table [3](#Tab3){ref-type="table"}). Of those, 100 were due to withdrawal of consent and 16 to noncompliance. Among the 332 non-patient-driven discontinuations, 210 were due to adverse events, 52 to reaching a clinical efficacy endpoint, 44 to investigator decision, and 26 to protocol violations. Discontinuation reasons for the entire ROCKET AF cohort are in Supplemental Table 2.Table 3Reasons for early permanent study drug discontinuation in the analysis cohortAll patients (*N* = 1181)Rivaroxaban (*N* = 572)Warfarin (*N* = 609)Discontinued study drug early448 (37.9%)213 (37.2%)235 (38.6%)Reason for discontinuation (% among discontinuing patients)Patient-driven discontinuation116 (25.9%)52 (24.4%)64 (27.2%) Consent withdrawn100 (22.3%)46 (21.6%)54 (23.0%) Noncompliant with study medication16 (3.6%)6 (2.8%)10 (4.3%) Lost to follow-up000Non-patient-driven discontinuation332 (74.1%)161 (75.6%)171 (72.8%) Adverse event210 (46.9%)109 (51.2%)101 (43.0%) Clinical efficacy endpoint reached52 (11.6%)24 (11.3%)28 (11.9%) Investigator decision44 (9.8%)19 (8.9%)25 (10.6%) Protocol violation26 (5.8%)9 (4.2%)17 (7.2%)Data presented as no. (%)

The relationship between satisfaction and discontinuation is presented in Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}. Although on three of the subscales (ACTS Burdens, ACTS Benefits, and TSQM II Effectiveness) there were numerically higher rates of discontinuations in the less satisfied group, there were no statistically significant differences in discontinuation rates between the more and the less satisfied groups for any of the six satisfaction subscales. The results of our sensitivity analysis (which compared patients who were above versus below median satisfaction) are displayed in Supplemental Table 3. In this analysis, too, there were no statistically significant differences in discontinuation rates between more and less satisfied patients.Table 4Association of patient satisfaction scales at 4 weeks with subsequent early study drug discontinuationQuestionnaire/ScaleCut-off^a^Not satisfied^b^Satisfied^b^HR (95% CI)^c^ Not satisfied vs. satisfied*P* value^c^ACTS Burdens  *N*42291152  Events/100 pt-years (total events)6.89 (4)5.41 (112)1.44 (0.44--3.46)0.50 Benefits  *N*12462719  Events/100 pt-years (total events)6.02 (51)5.07 (65)1.18 (0.81--1.71)0.38TSQM II Effectiveness  *N*67195986  Events/100 pt-years (total events)7.00 (23)5.16 (93)1.23 (0.76--1.91)0.38 Side Effects  *N*100326855  Events/100 pt-years (total events)5.55 (31)5.41 (85)0.99 (0.64--1.48)0.95Convenience  *N*67981083  Events/100 pt-years (total events)4.61 (8)5.52 (108)0.77 (0.34--1.48)0.48Global Satisfaction  *N*671491032  Events/100 pt-years (total events)5.32 (14)5.47 (102)0.95 (0.52--1.61)0.86*ACTS* Anti-Clot Treatment Scale, *CI* confidence interval, *HR* hazard ratio, *TSQM II* Treatment Satisfaction Questionnaire for Medication version II^a^Satisfaction is defined as a score at or above the cut-off^b^Groups are defined using "satisfied" or "not satisfied" survey answers (primary analysis; see Methods)^c^Hazard ratio and *P* value for discontinuation are from adjusted modelFig. 2Patient-driven discontinuation rate (events/100 patient-years) by satisfaction levels at 4 weeks (primary analysis)

Discussion {#Sec4}
==========

In this substudy of anticoagulation-related quality of life from the ROCKET AF trial, patients with AF who were randomly assigned in a double-blind fashion to rivaroxaban or warfarin reported no difference in satisfaction with study drug at 4 versus 24 weeks after enrollment. As expected given the double-blind trial design, similar satisfaction between patients randomized to rivaroxaban versus warfarin was observed. However, in contrast to our hypothesis, we found no association between anticoagulation satisfaction and patient-driven study drug discontinuation.

As patient-centered care assumes a more prominent role in treatment guidelines, the need to systematically integrate PROs in cardiovascular research has been emphasized \[[@CR2], [@CR15], [@CR16]\]. These results build on previous studies of patient satisfaction with anticoagulation. Earlier work has shown that some patients have lower perceived quality of life with warfarin \[[@CR31], [@CR32]\], validated PROs measuring satisfaction with warfarin and the DOACs \[[@CR24]--[@CR27]\], and suggested that patients have higher satisfaction with rivaroxaban versus warfarin across a number of indications \[[@CR17]--[@CR21]\]. Furthermore, studies have demonstrated low rates of drug adherence, both in clinical trials and in practice \[[@CR33]--[@CR38]\]. This study builds on these two lines of research by examining whether PROs measuring satisfaction predict anticoagulant nonadherence.

Although we did not find any significant relationship between study drug satisfaction and discontinuation, we did observe some nonsignificant associations. Higher satisfaction on ACTS Burdens, ACTS Benefits, and TSQM II Effectiveness were all nonsignificantly associated with lower discontinuation. This association for the TSQM II Effectiveness subscale was the largest and was present in both our primary and secondary analyses. This may suggest that patients would be willing to tolerate side effects and inconvenience as long as they believe that a drug is effective. Alternatively, it is possible that these previously validated anticoagulation satisfaction scales may not be as powerful predictors in AF as they are in thromboembolic disease. This observation may generate the hypothesis that patients who have already had DVT report higher satisfaction with anticoagulants, and more generally that efficacy is perceived as higher when a drug is used for secondary versus primary prevention. Further studies exploring this hypothesis and the impact of PROs and drug discontinuation should be studied in open-label trials with larger sample sizes.

Participants assigned to rivaroxaban and warfarin had similar satisfaction at 4 weeks and 24 weeks in this analysis likely because of the double-blind study design that included sophisticated sham INR testing in the rivaroxaban group. These results support that the blinding of the participants was preserved with this approach \[[@CR23]\]. Other studies of comparative satisfaction used conditions more similar to actual use, involving blood draws with warfarin but not with rivaroxaban \[[@CR17], [@CR18]\]. The similar satisfaction with warfarin and rivaroxaban on every satisfaction subscale suggests that the difference in satisfaction seen in other studies may be attributable to the increased monitoring with warfarin, rather than differences in drug side effects or other non-monitoring-related drug effects.

This study has several limitations. First, only a subset of trial participants from North America and Western Europe participated in the substudy, limiting the generalizability and statistical power. Second, there were a relatively small number of discontinuation events, further reducing statistical power. Third, given the small sample and few endpoint events it was not possible to evaluate the relationships between satisfaction, adherence, and other clinical outcomes.

Conclusions {#Sec5}
===========

In conclusion, in this substudy from ROCKET AF, no statistically significant association between self-reported study drug satisfaction and patient-driven study drug discontinuation was observed. As expected in a double-blind trial, no significant difference between satisfaction between the rivaroxaban group and the warfarin group was observed. Although these results were negative, the importance of PRO data, even in the context of blinded randomized controlled trials, will undoubtedly continue to increase. ROCKET AF successfully collected PRO data in a large clinical trial, and these results may provide important lessons for future clinical trials that collect and monitor PROs to ascertain satisfaction, and explore the relation of PROs to adherence and other clinical outcomes.
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